Clinical Trial

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Study acronym: SELECTIONLTE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
Protocol Amendment History 66 amendments
This ClinicalTrials.gov record has been amended 66 times since 2016-09-22; most recent amendment 2026-05-19.
Status change: Enrolling by Invitation → Active, Not Recruiting 2020-04-30
Status change: Recruiting → Enrolling by Invitation 2018-05-01
Status change: Not Yet Recruiting → Recruiting 2017-02-07
Trial Details
NCT Number NCT02914535
Lead Sponsor Alfasigma S.p.A.
Collaborators: Gilead Sciences
Conditions Ulcerative Colitis
Enrollment 1,173 participants
Start Date 2017-02-23
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-22